A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report
S. Kim(Moffitt Cancer Center), Andrew S. Brohl(Moffitt Cancer Center), Jane L. Messina(Moffitt Cancer Center), Zeynep Eroglu(City Of Hope National Medical Center), Kenneth Y. Tsai(Moffitt Cancer Center), Evan Wuthrick(Moffitt Cancer Center), Joseph Markowitz(Moffitt Cancer Center), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Dukagjin Blakaj(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Trevor Rose(Moffitt Cancer Center), J.J. Caudell(Moffitt Cancer Center), Jeffery S. Russell(Janssen (United States)), Masahiko Aoki(Moffitt Cancer Center), Harsh Shah(University of Utah), L.B. Harrison(Moffitt Cancer Center), D.-T. Chen(Moffitt Cancer Center)
Cited by 5
Related Papers
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
|Cancer|2016|375
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263
Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck: ASCO Guideline
|Journal of Clinical Oncology|2020|221